Copyright
©2014 Baishideng Publishing Group Inc.
World J Gastroenterol. Jun 7, 2014; 20(21): 6594-6601
Published online Jun 7, 2014. doi: 10.3748/wjg.v20.i21.6594
Published online Jun 7, 2014. doi: 10.3748/wjg.v20.i21.6594
Table 1 Clinical parameters of the study population n (%)
Parameter | Value |
Mean age (yr)1 | 51.9 ± 6.9 |
Male | 184 (82.1) |
Diagnosis | |
Hepatitis B | 197 (87.9) |
Hepatitis C | 13 (5.8) |
Others | 14 (6.3) |
GRWR1 | 1.21 ± 0.27 |
Child pugh score1 | 8.2 ± 2.4 |
MELD score1 | 12.8 ± 7.6 |
AFP (ng/mL)1 | 183.4 ± 762.7 |
PIVKA-II (mAU/mL)1 | 206.5 ± 1118.7 |
C-reactive protein (mg/dL)1 | 1.36 ± 2.74 |
Neutrophil lymphocyte ratio1 | 3.47 ± 4.68 |
Pretransplant treatment for HCC | 167 (74.6) |
Tumor number1 | 2.6 ± 2.4 |
Maximum tumor size (cm)1 | 3.2 ± 3.1 |
Microvascular invasion | 44 (21.3) |
Edmondson-steiner grade (III-IV) | 81 (42.9) |
Within the milan criteria | 133 (59.4) |
Follow-up duration (mo)1 | 48.9 ± 37.3 |
(median: 68, range: 6-139) |
Table 2 Disease-free survival and overall survival according to neutrophil-lymphocyte ratio and C-reactive protein
Disease-free survival | Overall survival | |||
χ2 | P value | χ2 | P value | |
Neutrophil-lymphocyte ratio (n = 224) | ||||
NLR ≥ 1 (n = 195) | 1.041 | 0.308 | 0.125 | 0.724 |
NLR ≥ 2 (n = 115) | 2.938 | 0.087 | 2.777 | 0.096 |
NLR ≥ 3 (n = 70) | 0.746 | 0.388 | 3.308 | 0.069 |
NLR ≥ 4 (n = 44) | 1.132 | 0.287 | 5.301 | 0.021 |
NLR ≥ 5 (n = 34) | 2.383 | 0.123 | 7.257 | 0.007 |
NLR ≥ 6 (n = 27) | 3.497 | 0.049 | 8.799 | 0.003 |
NLR ≥ 7 (n = 22) | 1.379 | 0.240 | 6.411 | 0.001 |
C-reactive protein (n = 145) | ||||
CRP ≥ 0.5 (n = 72) | 1.359 | 0.244 | 4.032 | 0.045 |
CRP ≥ 1.0 (n = 42) | 6.653 | 0.010 | 12.604 | < 0.001 |
CRP ≥ 2.0 (n = 25) | 6.974 | 0.008 | 6.728 | 0.009 |
Table 3 Clinicopathological characteristics according to Neutrophil-lymphocyte ratio and C-reactive protein n (%)
Parameters | NLR < 6 | NLR≥6 | P value | CRP < 1 | CRP≥1 | P value |
(n = 197) | (n = 27) | (n = 103) | (n = 42) | |||
Mean age (yr)1 | 51.8 ± 7.0 | 52.2 ± 6.3 | 0.748 | 52.4 ± 6.9 | 52.4 ± 6.8 | 0.992 |
Male | 164 (83.2) | 20 (74.1) | 0.243 | 81 (78.6) | 35 (83.3) | 0.522 |
Etiology (HBV) | 172 (87.3) | 25 (92.6) | 0.345 | 90 (87.4) | 37 (88.1) | 0.991 |
GRWR1 | 1.20 ± 0.27 | 1.24 ± 0.30 | 0.495 | 1.21 ± 0.29 | 1.23 ± 0.26 | 0.777 |
Total bilirubin (g/dL)1 | 3.8 ± 6.8 | 11.1 ± 12.5 | 0.006 | 3.2 ± 5.8 | 11.5 ± 12.2 | < 0.001 |
PT INR1 | 2.6 ± 15.3 | 1.7 ± 0.5 | 0.771 | 1.4 ± 0.3 | 6.6 ± 33.2 | 0.293 |
Child Pugh score1 | 7.9 ± 2.3 | 9.8 ± 2.2 | < 0.001 | 7.8 ± 2.4 | 9.9 ± 1.9 | < 0.001 |
MELD score1 | 11.7 ± 6.8 | 20.6 ± 8.8 | < 0.001 | 10.9 ± 6.0 | 19.4 ± 8.9 | < 0.001 |
AFP (ng/mL)1 | 142 ± 366 | 490 ± 1995 | 0.383 | 128 ± 381 | 346 ± 1593 | 0.389 |
NLR1 | 2.12 ± 1.19 | 13.3 ± 7.79 | < 0.001 | 2.54 ± 2.71 | 6.15 ± 7.37 | 0.003 |
CRP (mg/dL)1 | 1.03 ± 2.13 | 3.55 ± 4.76 | 0.035 | 0.33 ± 0.29 | 3.87 ± 4.13 | < 0.001 |
Tumor number1 | 2.5 ± 2.3 | 3.3 ± 2.8 | 0.162 | 2.7 ± 2.4 | 2.4 ± 2.1 | 0.352 |
Maximal tumor size1 | 3.10 ± 2.37 | 4.03 ± 6.13 | 0.441 | 2.9 ± 1.5 | 4.1 ± 5.8 | 0.475 |
Microvascular invasion (+) | 38 (21.0) | 6 (23.1) | 0.800 | 20 (21.1) | 6 (15.0) | 0.225 |
E-S grade (III-IV) | 94 (57.3) | 14 (56.0) | 0.901 | 38 (44.7) | 17 (45.9) | 0.415 |
Beyond the Milan criteria | 69 (36.5) | 14 (51.9) | 0.125 | 39 (39.0) | 15 (36.6) | 0.899 |
Pretransplant locoregional treatment | 146 (74.1) | 21 (77.8) | 0.682 | 81 (78.6) | 30 (71.4) | 0.352 |
Table 4 Prognostic factors for disease free survival and overall survival in the whole study population
Disease free survival | Overall survival | |||||
Univariate | Multivariate analysis | Univariate | Multivariate analysis | |||
P value | HR (95%CI) | P value | P value | HR (95%CI) | P value | |
Age ≥ 60 | 0.404 | 0.723 | ||||
Male gender | 0.196 | 2.086 (0.595-7.307) | 0.250 | 0.411 | ||
Etiology (HBV) | 0.977 | 0.775 | ||||
GRWR ≥ 1.0 | 0.551 | 0.639 | ||||
Child C | 0.978 | 0.810 | ||||
AFP ≥ 100 | 0.015 | 2.588 (1.187-5.645) | 0.017 | 0.048 | 1.567 (0.822-2.987) | 0.172 |
NLR ≥ 6 | 0.049 | 2.512 (0.987-6.391) | 0.053 | 0.003 | 2.896 (1.399-5.996) | 0.004 |
Pretransplant locoregional treatment | 0.017 | 4.604 (1.074-19.740) | 0.040 | 0.023 | 1.946 (0.804-4.713) | 0.140 |
Tumor number ≥ 2 | 0.604 | 0.913 | ||||
Tumor size ≥ 5 cm | < 0.001 | 6.014 (2.432-14.869) | < 0.001 | 0.001 | 2.206 (0.968-5.028) | 0.060 |
Microvascular invasion (+) | 0.024 | 1.369 (0.599-3.132) | 0.456 | 0.074 | 1.554 (0.769-3.141) | 0.220 |
E-S grade (III-IV) | 0.172 | 1.040 (0.470-2.302) | 0.923 | 0.082 | 1.371 (0.715-2.630) | 0.342 |
CRP ≥ 1.0 (n = 145) | 0.010 | < 0.001 |
Table 5 Prognostic factors for disease free survival and overall survival in patients with hepatocelluar carcinoma according to the Milan criteria
Disease free survival | Overall survival | |||||
Univariate | Multivariate analysis | Univariate | Multivariate analysis | |||
P value | HR (95%CI) | P value | P value | HR (95%CI) | P value | |
Within the Milan criteria | ||||||
AFP ≥ 100 | 0.475 | 0.471 | ||||
NLR ≥ 6 | 0.541 | 0.037 | 2.509 (0.945-6.658) | 0.065 | ||
Pretransplant locoregional treatment | 0.193 | 2.126 (0.587-7.710) | 0.251 | 0.257 | ||
Tumor number ≥ 2 | 0.764 | 0.459 | ||||
Tumor size ≥ 5 cm | < 0.001 | 6.980 (1.497-32.535) | 0.013 | 0.681 | ||
Microvascular invasion (+) | 0.619 | 0.307 | ||||
E-S grade (III-IV) | 0.835 | 0.592 | ||||
CRP ≥ 1.0 (n = 145) | 0.797 | 0.054 | ||||
Beyond the Milan criteria | ||||||
AFP ≥ 100 | 0.058 | 3.619 (1.184-11.063) | 0.024 | 0.082 | 2.456 (0.888-6.793) | 0.083 |
NLR ≥ 6 | 0.034 | 3.973 (1.288-12.249) | 0.016 | 0.045 | 4.685 (1.607-13.657) | 0.005 |
Pretransplant locoregional treatment | 0.096 | 0.972 | 0.086 | 0.971 | ||
Tumor number ≥ 2 | 0.001 | 0.429 (0.108-1.701) | 0.228 | 0.016 | 0.493 (0.121-2.001) | 0.322 |
Tumor size ≥ 5 cm | < 0.001 | 3.753 (0.901-15.626) | 0.069 | 0.003 | 2.354 (0.587-9.449) | 0.227 |
Microvascular invasion (+) | 0.226 | 0.318 | ||||
E-S grade (III-IV) | 0.083 | 2.191 (0.697-6.884) | 0.179 | 0.067 | 2.618 (0.895-7.651) | 0.079 |
CRP ≥ 1.0 (n = 145) | 0.004 | 0.001 |
- Citation: Na GH, Kim DG, Han JH, Kim EY, Lee SH, Hong TH, You YK. Inflammatory markers as selection criteria of hepatocellular carcinoma in living-donor liver transplantation. World J Gastroenterol 2014; 20(21): 6594-6601
- URL: https://www.wjgnet.com/1007-9327/full/v20/i21/6594.htm
- DOI: https://dx.doi.org/10.3748/wjg.v20.i21.6594